Genmab A/S (OTCMKTS:GNMSF - Get Free Report) saw a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 73,000 shares, a growth of 30.1% from the March 31st total of 56,100 shares. Approximately 0.1% of the company's stock are sold short. Based on an average trading volume of 16,800 shares, the days-to-cover ratio is currently 4.3 days.
Genmab A/S Price Performance
Shares of OTCMKTS GNMSF traded down $13.36 on Wednesday, hitting $207.15. The company's stock had a trading volume of 70 shares, compared to its average volume of 2,954. The company has a market capitalization of $13.69 billion, a price-to-earnings ratio of 11.82 and a beta of 1.02. The stock has a 50 day moving average of $201.00 and a 200-day moving average of $208.22. Genmab A/S has a 12-month low of $170.00 and a 12-month high of $305.09.
Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $5.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $5.24. Genmab A/S had a return on equity of 19.75% and a net margin of 36.30%.
Genmab A/S Company Profile
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
See Also
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
